Clinical Trial Update: Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 3]

View source ↗

Summary

Phase 3 trial of SPD489 for ADHD in adolescents aged 13-17 was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPD489

Snippet

Sponsor: Shire | Conditions: ADHD | Phase 3 | Status: WITHDRAWN